Curis, Inc. (CRIS)
| Previous Close | 6.02 |
| Open | 6.11 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 6.00 - 6.28 |
| 52 Week Range | 0.38 - 17.49 |
| Volume | |
| Avg. Volume | 29,327 |
| Market Cap | 36.072M |
| Beta (5Y Monthly) | 3.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.62 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.50 |
PR NewswireCuris to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.
- PR Newswire
Curis to Present at Upcoming Healthcare Conference in July
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET). A live webcast and archived replay will be available and can be accessed here or on the Events & Presentations section of Curis's website.
ZacksWhat Makes Curis (CRIS) a New Buy Stock
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
